«Виртуальная» периодическая болезнь

Authors: Рустам Мурадович Ниязов, Николай Николаевич Золотухин, Дарья Сергеевна Мамонькина, Асмар Айюбовна Мехралызаде, Лейла Мурадиновна Мисирова

Source: University Therapeutic Journal, Vol 7, Iss 3 (2025)

Subject Terms: семейная средиземноморская лихорадка, ССЛ, периодическая болезнь, ПБ, мутация в гене WEFV, пурин, Medicine

File Description: electronic resource

Relation: https://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/6678; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920

Access URL: https://doaj.org/article/4c26414ff61a490a97ec3ed893144d33

A clinical case of Crohn's disease with late-onset familial Mediterranean fever ; Клиническое наблюдение болезни Крона с поздним дебютом семейной средиземноморской лихорадки

Authors: Ganich E.G., Davydov D.A., Kuznetsova D.A., Gorbacheva D.S., Sidorenko D.V., Lapin S.V., Nazarov V.D., Deviatkina Y.A., Shchukina O.B.

Contributors: 1

Source: Almanac of Clinical Medicine; Vol 53, No 4 (2025); 217-225 ; Альманах клинической медицины; Vol 53, No 4 (2025); 217-225 ; 2587-9294 ; 2072-0505

Subject Terms: familial Mediterranean fever, MEFV, Crohn's disease, colchicine resistance, upadacitinib, canakinumab, ustekinumab, семейная средиземноморская лихорадка, болезнь Крона, резистентность к колхицину, упадацитиниб, канакинумаб, устекинумаб

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17418/1745; https://almclinmed.ru/jour/article/view/17418/1758; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160358; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160359; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160360; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160638; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160639; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160640; https://almclinmed.ru/jour/article/downloadSuppFile/17418/160641; https://almclinmed.ru/jour/article/view/17418

Availability: https://almclinmed.ru/jour/article/view/17418
https://doi.org/10.18786/2072-0505-2025-53-014

Hereditary periodic fevers in children ; Наследственные периодические лихорадки у детей

Authors: S. B. Krutikhina, M. A. Kudryashova, С. Б. Крутихина, М. А. Кудряшова

Source: Meditsinskiy sovet = Medical Council; № 1 (2024); 276–280 ; Медицинский Совет; № 1 (2024); 276–280 ; 2658-5790 ; 2079-701X

Subject Terms: TRAPS, ibuprofen, auto-inflammatory diseases, family mediterranean fever, HIDS, MKD, CAPS, ибупрофен, аутовоспалительные заболевания, семейная средиземноморская лихорадка

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8106/7164; Захарова ИН, Османов ИМ, Творогова ТМ, Горяйнова АН, Дмитриева ЮА, Воробьева АС, Короид НВ. Длительная лихорадка у ребенка: в чем причина, как обследовать, лечить или не лечить? Медицинский совет. 2020;(10):151–162. https://doi.org/10.21518/2079-701X-2020-10-151-162.; Сомова ТМ. Аутовоспалительное заболевание – синдром гипериммуноглобулинемии D. Медицинский вестник Юга России. 2022;13(2):141–145. https://doi.org/10.21886/2219-8075-2022-13-2-141-145; Салугина СО, Федоров ЕС, Агафонова ЕМ. Моногенные аутовоспалительные заболевания у детей и взрослых: что необходимо знать ревматологу. Научно-практическая ревматология. 2019;57(2):125–132. https://doi.org/10.14412/1995-4484-2019-125-132.; Гатторно М. Аутовоспалительные заболевания у детей. Вопросы современной педиатрии. 2014;13(2):55–64. https://doi.org/10.14412/1995-4484-2019-125-132.; Крутихина СБ, Горелов АВ, Яблокова ЕА, Тюрина ЕН, Мелешкина АВ, Чебышева СН, Савватеева ОА. Семейная средиземноморская лихорадка у детей: современные методы диагностики и подходы к терапии болевого абдоминального синдрома. Вопросы детской диетологии. 2021;19(2):76–82. https://doi.org/10.20953/1727-5784-2021-2-76-82.; Lancieri M, Bustaffa M, Palmeri S, Prigione I, Penco F, Papa R et al. An Update on Familial Mediterranean Fever. Int J Mol Sci. 2023;24(11):9584. https://doi.org/10.3390/ijms24119584.; Diaz A, Hu C, Kastner DL, Schaner P, Reginato AM, Richards N, Gumucio DL. Lipopolysaccharide-Induced Expression of Multiple Alternatively Spliced MEFV Transcripts in Human Synovial Fibroblasts: A Prominent Splice Isoform Lacks the C-Terminal Domain That Is Highly Mutated in Familial Mediterranean Fever. Arthritis Rheum. 2004;50(11):3679–3689. https://doi.org/10.1002/art.20600.; Zadeh N, Getzug T, Grody WW. Diagnosis and Management of Familial Mediterranean Fever: Integrating Medical Genetics in a Dedicated Interdisciplinary Clinic. Genet Med. 2011;13(3):263–269. https://doi.org/10.1097/GIM.0b013e31820e27b1.; Di Donato G, d’Angelo DM, Breda L, Chiarelli F. Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. Int J Mol Sci. 2021;22(12):6360. https://doi.org/10.3390/ijms22126360.; Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14(1):30. https://doi.org/10.1186/s12969-016-0091-7.; Федоров ЕС, Салугина СО, Соболева МК. Семейный случай TRAPS-синдрома в российской популяции. Современная ревматология. 2015;9(1):60–65. https://doi.org/10.14412/1996-7012-2015-1-60-65.; Shu Z, Zhang Y, Han T, Li Y, Piao Y, Sun F et al. The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China. Front Immunol. 2023;14:1267933. https://doi.org/10.3389/fimmu.2023.1267933.; Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al. Treatment of autoinflammatory diseases: results from the eurofever registry and a literature review. Ann Rheum Dis. 2013;72(5):678–685. https://doi.org/10.1136/annrheumdis-2011-201268.; Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al. EULAR recommendations for the management of familial mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690.; Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren PA, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35(8):691–712. https://doi.org/10.1016/j.tibtech.2017.04.007.; Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrinassociated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499–1506. https://doi.org/10.1093/rheumatology/kew208.; Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. Arthritis Care Res (Hoboken). 2017;69(4):578–586. https://doi.org/10.1002/acr.23120.; Nedjai B, Quillinan N, Coughlan RJ, Church L, McDermott MF, Hitman GA et al. Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A. Adv Exp Med Biol. 2011;691:409–419. https://doi.org/10.1007/978-1-4419-6612-4_43.; Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–3052. https://doi.org/10.1172/JCI98814.; Shendi HM, Devlin LA, Edgar JD. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J Clin Rheumatol. 2014;20(2):103–105. https://doi.org/10.1097/01.RHU.0000442576.41537.de.; Kaplan E, Mukamel M, Barash J, Brik R, Padeh S, Berkun Y et al. Protracted febrile myalgia in children and young adults with familial mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol. 2007;25(4):114–117. Available at: https://pubmed.ncbi.nlm.nih.gov/17949564.; Морозова ТЕ, Андрущишина ТБ, Антипова ЕК. Ибупрофен: безопасность и эффективность применения в широкой клинической практике. Терапевтический архив. 2013;85(3):118–124. Режим доступа: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2013/3/030040-36602013322.

Availability: https://www.med-sovet.pro/jour/article/view/8106
https://doi.org/10.21518/ms2024-024

Late onset familial Mediterranian fever: a clinical case ; Клиническое наблюдение семейной средиземноморской лихорадки с поздним дебютом

Authors: Grinevich V.B., Gubonina I.V., Shperling M.I., Lapteva S.I., Kolodin T.V., Poluektov M.V.

Source: Almanac of Clinical Medicine; Vol 49, No 7 (2021); 496-502 ; Альманах клинической медицины; Vol 49, No 7 (2021); 496-502 ; 2587-9294 ; 2072-0505

Subject Terms: familial Mediterranean fever, MEFV, AA amyloidosis, colchicine, семейная средиземноморская лихорадка, АА-амилоидоз, колхицин

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1589/1404; https://almclinmed.ru/jour/article/downloadSuppFile/1589/2621; https://almclinmed.ru/jour/article/downloadSuppFile/1589/2622; https://almclinmed.ru/jour/article/view/1589

Availability: https://almclinmed.ru/jour/article/view/1589
https://doi.org/10.18786/2072-0505-2021-49-052

The Clinical Course and Outcomes of Familial Mediterranean Fever in Crimean Tatar Patients: Preliminary Results of Case Series ; Течение и исходы семейной средиземноморской лихорадки у пациентов крымско-татарской национальности: предварительные результаты исследования серии случаев

Authors: Olga V. Zhogova, Sergey V. Ivanovskiy, Natalya V. Lagunova, Anastasia V. Tumakova, Mikhail M. Kostik, О. В. Жогова, С. В. Ивановский, Н. В. Лагунова, А. В. Тумакова, М. М. Костик

Contributors: The article has been funded by Novartis. Company employees did not participate in planning, conducting and discussing of the results of this study., Статья опубликована при поддержке компании «Новартис». Сотрудники компании не участвовали в планировании, проведении и обсуждении результатов настоящего исследования.

Source: Current Pediatrics; Том 19, № 3 (2020); 200-206 ; Вопросы современной педиатрии; Том 19, № 3 (2020); 200-206 ; 1682-5535 ; 1682-5527

Subject Terms: аутовоспалительные заболевания, familial Mediterranean fever, Crimean Tatar, periodic fever, autoinflammatory diseases, семейная средиземноморская лихорадка, крымские татары, периодическая лихорадка

File Description: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

Relation: https://vsp.spr-journal.ru/jour/article/view/2396/941; https://vsp.spr-journal.ru/jour/article/view/2396/1000; Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol. 2011;7(8):469–478. doi:10.1038/nrrheum.2011.94.; Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103(26):9982–9987. doi:10.1073/pnas.0602081103.; Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–253. doi:10.1016/0002-9343(67)90167-2.; Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553–555. doi:10.1038/sj.ejhg.5200674.; Touitou I. Standardized testing for mutations in familial Mediterranean fever. Clin Chem. 2003;49(11):1781–1782. doi:10.1373/clinchem.2003.025791.; Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–483. doi:10.1038/sj.ejhg.5200658.; The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. doi:10.1016/s0092-8674(00)80539-5.; French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. doi:10.1038/ng0997-25.; Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol. 2003;30(1):185–190.; Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60(6):1862–1866. doi:10.1002/art.24570.; Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60(6):1851–1861. doi:10.1002/art.24569.; Ece A, Cakmak E, Uluca U, et al. The MEFV mutations and their clinical correlations in children with familial Mediterranean fever in southeast Turkey. Rheumatol Int. 2014;34(2):207–212. doi:10.1007/s00296-013-2858-1.; Kastner DL, Aksentijevich I. Intermittent and periodic arthritis syndromes. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia, USA: Lippincott Williams and Wilkins; 2005. pp. 1411–1461.; Жогова О.В., Лагунова Н.В., Ивановский С.В. и др. Семейная средиземноморская лихорадка в Республике Крым: описание серии случаев с анализом исторических и этнографических аспектов заболевания. Научно-практическая ревматология. — 2019. — Т. 57, № 3. — С. 339–344.; Tsuchiya-Suzuki A, Yazaki M, Nakamura A, et al. Clinical and genetic features of familial Mediterranean fever in Japan. J Rheumatol. 2009;36(8):1671–1676. doi:10.3899/jrheum.081278.; Lim AL, Jang HJ, Han JW, et al. Familial Mediterranean fever: the first adult case in Korea. J Korean Med Sci. 2012;27(11): 1424–1427. doi:10.3346/jkms.2012.27.11.1424.; Li J, Zhang Y, Wang W, et al. Three cases with familial Mediterranean fever misdiagnosed as juvenile idiopathic arthritis. Zhonghua Er Ke Za Zhi. 2017;55(5):383–387. doi:10.3760/cma.j.issn.0578-1310.2017.05.015.; Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78(8): 1025–1032. doi:10.1136/annrheumdis-2019-215048.; Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. doi:10.1136/annrheumdis-2015-208690.; Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10): 1879–1885. doi:10.1002/art.1780401023.; Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998;27(2): 92–97. doi:10.1080/030097498440949.; Yalcinkaya F, Cakar N, Misirlioglu M, et al. Genotypephenotype correlation in a large group of Turkish patients with familial mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology (Oxford). 2000;39(1):67–72. doi:10.1093/rheumatology/39.1.67.; Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73(4):662–667. doi:10.1136/annrheumdis-2012-202708.; Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. J Clin Rheumatol. 2013 Aug;19(5):246-51. doi:10.1097/RHU.0b013e31829ce005.; Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever are they more frequent? Semin Arthritis Rheum. 2007;36(5): 316–321. doi:10.1016/j.semarthrit.2006.11.002.; Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38(1):67–74. doi:10.1007/s00296-017-3796-0.; Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155(7):540–544. doi:10.1007/bf01957901.; Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11. doi:10.1097/01.md.0000152370.84628.0c.; Mukhin NA, Kozlovskaya LV, Bogdanova MV, et al. Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatol Int. 2015;35(7):1257–1261. doi:10.1007/s00296-014-3205-x.; Eshed I, Rosman Y, Livneh A, et al. Exertional leg pain in familial Mediterranean fever: a manifestation of an underlying enthesopathy and a marker of more severe disease. Arthritis Rheumatol. 2014;66(11):3221–3226. doi:10.1002/art.38797.; Jarjour RA, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype-genotype correlation. Rheumatol Int. 2015; 35(4):629–634. doi:10.1007/s00296-014-3116-x.; Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci. 2009;13 Suppl 1:51–53.; Colak S, Tekgoz E, Cinar M, Yilmaz S. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients. Mod Rheumatol. 2020:1–3. doi:10.1080/14397595.2019.1709258.; Ugurlu S, Hacioglu A, Adibnia Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017;12(1):105. doi:10.1186/s13023-017-0642-0.; Akar S, Cetin P, Kalyoncu U, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in Familial Mediterranean Fever patients. Arthritis Care Res (Hoboken). 2018; 70(7):1090–1094. doi:10.1002/acr.23446.; Gul A. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):296-303. doi:10.1016/j.berh.2016.09.001.; De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908–1919. doi:10.1056/NEJMoa1706314.; Laskari K, Boura P, Dalekos GN. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. J Rheumatol. 2017;44(1):102–109. doi:10.3899/jrheum.160518.

Availability: https://vsp.spr-journal.ru/jour/article/view/2396
https://doi.org/10.15690/vsp.v19i3.2115

Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case ; Терапия канакинумабом сестер с колхицинрезистентной формой семейной средиземноморской лихорадки: клиническое наблюдение

Authors: Elena A. Ligostaeva, Nadezhda A. Tsurikova, Irina A. Tsiganok, Nataliya N. Kobzeva, Vadim Yu. Avdeenko, Е. А. Лигостаева, Н. А. Цурикова, И. А. Цыганок, Н. Н. Кобзева, В. Ю. Авдеенко

Contributors: Not specified, Не указан

Source: Current Pediatrics; Том 18, № 5 (2019); 362-368 ; Вопросы современной педиатрии; Том 18, № 5 (2019); 362-368 ; 1682-5535 ; 1682-5527

Subject Terms: нежелательные реакции, familial Mediterranean fever, clinical case, periodic disease, colchicine, canakinumab, interleukin-1, disease activity, adverse effect, семейная средиземноморская лихорадка, клинический случай, периодическая болезнь, колхицин, канакинумаб, интерлейкин 1, активность болезни

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2234/896; Chae JJ, Wood G, Richard K, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kB through its N-terminal fragment. Blood. 2008;112:1794-1803. doi:10.1182/blood-2008-01-134932.; Лобанова О.С., Волошинова Е.В. Некоторые особенности течения семейной средиземноморской лихорадки, осложненной развитием АА-амилоидоза // Архивъ внутренней медицины. — 2015. — № 1. — С. 7-11.; Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the World. Arthritis Rheum. 2009;61(10):1447-1453. doi:10.1002/art.24458.; Zadeh N, Getzug T, Grody WW. Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med. 2011;13(3):263-269. doi:10.1097/GIM.0b013e31820e27b1.; Ozen S, Hoffman HM, Frenkel J, Kastner D. Familial Mediterranean Fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. Ann Rheum Dis. 2006;65(7):961-964. doi:10.1136/ard.2006.052688.; Kuijk LM, Hoffman HL, Neven B, Frenkel J. Episodic Autoinflammatory Disorders in Children. In: Cimas R, Lehman T (eds). Handbook of Systemic Autoimmune Disease. Vol. 6. Pediatrcs in Systemic Autoimmune Disease. Elselvier; 2008. Рр. 119-135.; Ozen S, Frenkel J, Ruperto N, et al. The Eurofever project: towards better care for autoinflammatory disease. Eur J Pediatr. 2011; 170(4):445-452. doi:10.1007/s00431-0111411-z.; Janeway TC, Mosenthal H. Unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of nitrogen metabolism. Trans Assoc Am Physicians. 1908;23:504-518.; Reimann HA. Periodic disease; a probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. J Am Med Assoc. 1948;136(4):239-244. doi:10.1001/jama.1948.02890210023004.; Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473-483. doi:10.1038/sj.ejhg.5200658.; Centola M, Wood G, Frucht DM, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223-3231. doi:10.1182/blood.v95.10.3223.010k26_3223_3231.; Diaz A, Hu C, Kastner DL, et al. Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum. 2004;50(11):3679-3689. doi:10.1002/art.20600.; Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002; 61(1):79-81. doi:10.1136/ard.61.1.79.; The International FMF Consortium. Ancient missense mutation in a new member of the RoReT gene family are likely to cause Familial Mediterranean Fever. Cell. 1997;90(4):797-807. doi:10.1016/s0092-8674(00)80539-5.; Федоров Е.С., Салугина С.О., Кузьмина Н.Н. Семейная средиземноморская лихорадка (периодическая болезнь): современный взгляд на проблему // Современная ревматология. — 2013. — Т. 7. — № 1. — С. 24-30. doi:10.14412/1996-7012-2013-2363.; Park YH, Wood G, Kastner D, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914-921. doi:10.1038/ni.3457.; Omenetti A, Carta S, Delfino L, et al. Increased NLRP3-dependent interleukin 1p secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis. 2014;73(2): 462-469. doi:10.1136/annrheumdis-2012202774.; Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Meditarranean fever. Ann Rheum Dis. 2016;75(4):644-651. doi:10.1136/annrheumdis-2015-208690.; Simon A, et al. Familial autoinflammatory syndromes. In: Fires-tein G, Budd R, Gabriel SE, et al, eds. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders; 2008. Рр. 1863-1882.; Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis. 2015;10:34. doi:10.1186/s13023-015-0252-7.; Щербакова М.Ю., Ярошевская О.Ю., Гуревич О.Е., и др. Случай периодической болезни с исходом в амилоидоз у мальчика 15 лет // Педиатрия. Журнал им. Г.Н. Сперанского. — 2006. — № 4. — С. 111-114.; French FMF Consorcium. A candidate gene for Familial Mediterranean Fever. J Nat Genet. 1997;17(1):25-31. doi:10.1038/ng0997-25.; Berdeli A, Mukctarova G, Oz A, Musayev S. MEFV gene mutation distrubution in Azerbaijan population. Pediatr Rheumatol. 2015; 13(Suppl 1):127. doi:10.1186/1546-0096-13-S1-P127.; Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387-391. doi:10.1016/j.semarthrit.2013.04.011.; Костик М.М., Жогова О.В., Лагунова Н.В., и др. Семейная средиземноморская лихорадка: современные подходы к диагностике и лечению // Вопросы современной педиатрии. — 2018. — Т. 17. — № 5. — С. 371-380. doi:10.15690/vsp.v17i5.1953.; Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S77-86.; Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533-541. doi:10.7326/0003-4819-157-8-201210160-00003.; ClinicalTrials.gov. Study of efficacy and safety of Canakinumab in patients with hereditary periodic fevers. ClinicalTrials.gov Identifier: NCT02059291 [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02059291.; Gul A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinu-mab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243. doi:10.1186/s13075-015-0765-4.; Jarjour RA, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype-genotype correlation. Rheumatol Int. 2015; 35(4):629-634. doi:10.1007/s00296-014-3116-x.; Celkan T, Celik M, Kasapcopur O, et al. The anemia of familial Mediterranean fever disease. Pediatr Hematol Onco. 2005;22(8): 657-665. doi:10.1080/08880010500278681.; Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018; 38(1):67-74. doi:10.1007/s00296-017-3796-0.; Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48(4):395-398. doi:10.1093/rheu-matology/ken509.; Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155(7):540-544. doi:10.1007/bf01957901.; Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1-11. doi:10.1097/01.md.0000152370.84628.0c.

Availability: https://vsp.spr-journal.ru/jour/article/view/2234
https://doi.org/10.15690/vsp.v18i5.2060

PROSPECTS FOR USING COLCHICINE IN MEDICINE: NEW EVIDENCE ; Перспективы применения колхицина в медицине: новые данные

Authors: Z. S. Alekberova, E. L. Nasonov, З. С. Алекберова, Е. Л. Насонов

Source: Rheumatology Science and Practice; Vol 58, No 2 (2020); 183-190 ; Научно-практическая ревматология; Vol 58, No 2 (2020); 183-190 ; 1995-4492 ; 1995-4484

Subject Terms: атеросклероз, autoinflammatory diseases, gout, Familial Mediterranean Fever, Behсet's disease, atherosclerosis, аутовоспалительные заболевания, подагра, семейная средиземноморская лихорадка, болезнь Бехчета

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2876/1952; Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-60. doi:10.1136/pgmj.2006.052688; Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-24. doi:10.1038/ni.3731; Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832-42. doi:10.1038/ni.3777; McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:1242-8. doi:10.1371/journal.pmed.0030297; Kahlenberg JM, Kang I. Clinicopathologic significance of inflammasome activation in autoimmune diseases. Arthritis Rheum. 2019 Sep 28. doi:10.1002/art.41127; Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi:10.1136/annrheumdis-2017-211555; Насонов ЕЛ. Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний. Терапевтический архив. 2019;91(8):98-107. doi:10.26442/00403660.2019.08.000406 [Nasonov EL. New directions of pharmacotherapy of immuneinflammatory rheumatic diseases. Therapeutic Archive. 2019;91(8):98-107. doi:10.26442/00403660.2019.08.000406 (In Russ.)].; Hernandez-Santana YE, Giannoudaki E, Leon G, et al. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol. 2019;49(9):1306-20. doi:10.1002/eji.201848056; Roubille F, Kritikou E, Busseuil D, et al. Colchicine: an old wine in a new bottle? Antiinflam Antiallerg Agents Med Chem. 2013;12:14-23. doi:10.2174/1871523011312010004; Leung YY, Yao Hui LL, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341-50. doi:10.1016/j.semarthrit.2015.06.013; Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24(6):659-63. doi:10.2174/138161282466618012; Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407-20. doi:10.1038/nri.2016.58; Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-52. doi:10.1038/nrd3800; Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. doi:10.1038/s41584-019-0277-8; Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi:10.14412/1995-4484-2016-60-77; Stack J, Ryan J, McCarthy G. Colchicine: New Insight to an old drug. Am J Ther. 2015;22(5):e151-157. doi:10.1097/01.mjt.0000433937.07244.e1; Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi:10.1038/s41572-019-0115-y 18. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010;233(1):218-32. doi:10.1111/j.0105-2896.2009.00860.x; Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465-79. doi:10.1016/j.clinthera.2014.07.017; Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-4. doi:10.1111/j.1445-5994.1987.tb01232.x; Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi:10.1002/art.27327; Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447-61. doi:10.1002/acr.21773; Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. doi:10.1136/annrheumdis-2016-209707; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.; Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32.; Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-14. doi:10.1002/art.1780170517; Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of Colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11:104-7.; Roddy E, Mallen CD; CONTACT trial authors. Naproxen or low-dose colchicine for gout flares in primary care? Response to: 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care' by Parperis et al. Ann Rheum Dis. 2019 Dec 4. doi:10.1136/annrheumdis-2019-216671; Wortmann RL, MacDonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32:2386-97. doi:10.1016/j.clinthera.2011.01.008; Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-9. doi:10.14412/1995-4484-2017-600-609; McCarthy GM, Dunne A. Calcium crystal deposition diseases – beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi:10.1038/s41584-018-0078-5; Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571-5. doi:10.1136/ard.2010.139360; Владимиров СА, Елисеев МС. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-52. doi:10.14412/1995-4484-2018-746-752; Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020;72(2):220-33. doi:10.1002/art.41142; Migliore A, Gigliucci G, Alekseeva L, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019 Dec 19;11:1759720X19893800. doi:10.1177/1759720X19893800; Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi:10.1016/j.joca.2019.06.011; Conway R, McCarthy GM. Calcium-containing crystals and osteoarthritis: an unhealthy alliance. Curr Rheumatol Rep. 2018;20(3):13. doi:10.1007/s11926-018-0721-9; Frallonardo P, Ramonda R, Peruzzo L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clin Rheumatol. 2018;37(10):2847-53. doi:10.1007/s10067-018-4166-3; McAllister MJ, Chemaly M, Eakin AJ, et al. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage. 2018;26(5):612-9. doi:10.1016/j.joca.2018.02.901; Ghouri A, Conaghan PG. Treating osteoarthritis pain: recent approaches using pharmacological therapies. Clin Exp Rheumatol. 2019;37 Suppl 120(5):124-9.; Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019 Jun 21;8. doi:10.12688/f1000research.18831.1; Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80-9. doi:10.1097/BOR.0000000000000567; Еzen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253. doi:10.3389/fimmu.2017.00253; Grattagliano I, Bonfrate L, Ruggiero V, et al. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89-97. doi:10.1038/clpt.2013.148; El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF). Orphanet J Rare Dis. 2019;14(1):224. doi:10.1186/s13023-019-1201-7; Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644-51. doi:10.1136/annrheumdis-2015-208690; Ozaltin F, Bilginer Y, Gü lhan B, et al. Diagnostic validity of colchicine in patients with Familial Mediterranean fever. Clin Rheumatol. 2014;33(7):969-74. doi:10.1007/s10067-014-2598-y; Ali NS, Sartori-Valinotti JC, Bruce AJ. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. Clin Dermatol. 2016;34(4):482-6. doi:10.1016/j.clindermatol.2016.02.021; Manthiram K, Lapidus S, Edwards KC. Unraveling the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis through genetic, immunologic, and microbiologic discoveries: an update. Curr Opin Rheumatol. 2017;29(5):493-9. doi:10.1097/BOR.0000000000000418; Adrovic A, Sahin S, Barut K, Kasapcopur O. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: shared features and main differences. Rheumatol Int. 2019;39(1):29-36. doi:10.1007/s00296-018-4105-2; Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum. 2016;45(4):471-4. doi:10.1016/j.semarthrit.2015.07.005; Dusser P, Hengten V, Neven B, Kone-Paut I. Is colchicine an effective treatment in Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical adenitis (PFAPA) syndrome? Joint Bone Spine. 2016;83(4):406-11. doi:10.1016/j.jbspin.2015.08.017; Gaggiano C, Rigante D, Sota J, et al. Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clin Rheumatol. 2019;38(1):11-7. doi:10.1007/s10067-018-4361-2; Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107-19. doi:10.1038/nrrheum.2018.3; Алекберова ЗС. Болезнь Великого шелкового пути: от преданий в XXI век. Научно-практическая ревматология. 2015;53(1):5-8. doi:10.14412/1995-4484-2015-1-4; Алекберова ЗС. Болезнь Бехчета (лекция). Научно-практическая ревматология. 2013;51(1):52-8. doi:10.14412/1995-4484-2013-1202; Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413-8. doi:10.1007/s00281-015-0502-8. Epub 2015 Jun 12.; Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome. Semin Arthritis Rheum. 2019;48(4):752-62. doi:10.1016/j.semarthrit.2018.05.008; Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 ;77(6):808-18. doi:10.1136/annrheumdis-2018-213225; Лисицына ТА, Алекберова ЗС, Голоева РГ. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019;57(2):133-41. doi:10.14412/1995-4484-2019-133-141; Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-7. doi:10.1007/s10067-016-3506-4; Fontes V, Machet L, Huttenberger B, et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002;129:1365-9.; Pakfetrat A, Mansourian A, Momen-Heravi F, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clin Invest Med. 2010;33:E189-95. doi:10.25011/cim.v33i3.13725; Robinson KP, Chan JJ. Colchicine in dermatology: A review. J Dermatol. 2018;59(4):278-85. doi:10.1111/ajd.12795; Dasgeb B, Kornreich D, McGuinn K, et al. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178(2):350-6. doi:10.1111/bjd.15896; Kuemmerle-Descner JB, Schock AL, Nansmann S, Benseler SM. Colchicine: an effective treatment option for unclassified autoinflammatory disease in children. Ann Rheum Dis. 2018. doi:10.1136/annrheumdis-2018-eular.7473; Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25. doi:10.1016/j.jacc.2013.08.726; Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018 Feb;269:262-71. doi:10.1016/j.atherosclerosis.2017.12.027; Nidorf SM, Thompson PL. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther. 2019;41(1):41-8. doi:10.1016/j.clinthera.2018.11.016; Adler Y, Charron P, Imazio M, et al. European Society of C 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-64. doi:10.1093/eurheartj/ehv318; Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev. 2015;14(2):90-7. doi:10.1016/j.autrev.2014.10.005; Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. doi:10.1016/S0140-6736(13)62709-9; Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-23. doi:10.1001/jama.2014.11026; Izadi Amoli A, Bozorgi A, HajHossein Talasaz A, et al. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: a randomized, placebo-controlled trial. Am Heart J. 2015;170(6):1195-201. doi:10.1016/j.ahj.2015.09.020; Finkelstein Y, Shemesh J, Mahlab K, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27(8):791-4. doi:10.1007/s00059-002-2376-5; Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987-91. doi:10.1001/archinte.165.17.1987; Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-6. doi:10.1161/CIRCULATIONAHA.105.542738; Imazio M, Trinchero R, Brucato A, et al. COlchicine for the prevention of the post- pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749-54. doi:10.1093/eurheartj/ehq319; Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. doi:10.7326/0003-4819-155-7-201110040-00359; Imazio M, Brucato A, Cemin R, et al. Investigators I. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. doi:10.1056/NEJMoa1208536; Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Metaanalysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19(1):207. doi:10.1186/s12872-019-1190-4; Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34:1186-97. doi:10.1093/eurheartj/ehs372; Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation 2011;124:1830-7. doi:10.1161/CIRCULATIONAHA.111.026070; Syed FF, Schaff HV, Oh JK. Constrictive pericarditis – a curable diastolic heart failure. Nat Rev Cardiol. 2014;11:530-44. doi:10.1038/nrcardio.2014.100; Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63-6. doi:10.1038/s41577-018-0098-z; Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18:733-44. doi:10.1038/s41577-018-0065-8; Deftereos SG, Vrachatis DA, Angelidis C, et al. The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther. 2019;41(1):21-9. doi:10.1016/j.clinthera.2018.08.008; Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi:10.1016/j.jacc.2009.09.009; Насонов ЕЛ. Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12.; Libby PJ. A interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Amer Coll Cardiol. 2017;70(18):2278-89. doi:10.1016/j.jacc.2017.09.028; Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in stable coronary artery disease. Clin Ther. 2019;41(1):30-40. doi:10.1016/j.clinthera.2018.09.011; Vaidya K, Martinez G, Patel S. The role of colchicine in acute coronary syndromes. Clin Ther. 2019;41(1):11-20. doi:10.1016/j.clinthera.2018.07.023; Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. In: Hemkens LG, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016.; Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi:10.1016/j.jacc.2012.10.027; Vaidya K, Arnott C, Martinez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT Coronary Angiography Study. JACC Cardiovascular Imaging 2017 Oct 14. doi:10.1016/j.jcmg.2017.08.013; Deftereos S, Giannopoulos G, Angelidis C, et al. AntiInflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132:1395-403. doi:10.1161/CIRCULATIONAHA.115.017611; Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of lowdose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505. doi:10.1056/NEJMoa1912388; Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. doi:10.1056/NEJMoa1707914; Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62-9. doi:10.1016/j.ahj.2019.06.003; Nidorf SM, Fiolet ATL, Eikelboom JW, et al; LoDoCo2 Investigators. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46-56. doi:10.1016/j.ahj.2019.09.011; Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a therapeutic target in atherosclerosis. J Clin Med. 2019;8(8). doi:10.3390/jcm8081109; De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162-4. doi:10.1136/ard.2009.122770; Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251-9. doi:10.1093/rheumatology/ket293; Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111-7. doi:10.1093/rheumatology/kes169; Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458-64. doi:10.3899/jrheum.111533; Solomon DH, Liu C-C, Kuo I-H, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75:1674-9. doi:10.1136/annrheumdis-2015-207984; Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-42. doi:10.7326/M18-1167; Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-14. doi:10.3109/15563650.2010.495348; Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636-44. doi:10.1136/annrheumdis-2015-207546 110. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-89. doi:10.1038/s41577-019-0165-0

Availability: https://rsp.mediar-press.net/rsp/article/view/2876
https://doi.org/10.14412/1995-4484-2020-183-190

Challenging diagnosis: coexistence of two rare diseases - familial mediterranean fever and loyez-dietz syndrome type 3 ; Диагностические трудности: сосуществование двух редких заболеваний - семейной средиземноморской лихорадки и синдрома Лойса-Дитца 3 типа ; Difficulté de diagnostic: cohérence de deux maladies rares – fièvre méditerranée familiale et la syndrome Loeys-Dietz type 3

Authors: REVENCO, Ninel, ANDRIES, Lucia, SACARA, Victoria, DORIF, Alexandr, BARBA, Doina, EREMCIUC, Rodica, GAIDARJI, Olga

Source: One Health & Risk Management ; Vol. 1 No. 2 (2020); 68-72 ; Vol 1 Nr 2 (2020); 68-72 ; Том 1 № 2 (2020); 68-72 ; 2587-3466 ; 2587-3458

Subject Terms: autoinflammatory diseases, familial Mediterranean fever, children, maladies auto-inflammatoires, fièvre méditerranée familiale, enfants, аутовоспалительные заболевания, семейная средиземноморская лихорадка, дети

File Description: application/pdf

Relation: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/74/39

Availability: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/74
https://doi.org/10.38045/ohrm.2020.1.18

РАЗРАБОТКА КЛЕТОЧНОЙ МОДЕЛИ ДЛЯ ИЗУЧЕНИЯ СЕМЕЙНОЙ СРЕДИЗЕМНОМОРСКОЙ ЛИХОРАДКИ

Subject Terms: секвенирование, клеточное репрограммирование, клеточные линии, Familial Mediterranean fever – FMF, cell reprogramming, Семейная средиземноморская лихорадка – ССЛ, cell lines, sequencing

КЛИНИЧЕСКИЙ СЛУЧАЙ НЕТИПИЧНОГО ТЕЧЕНИЯ СЕМЕЙНОЙ СРЕДИЗЕМНОМОРСКОЙ ЛИХОРАДКИ У ПОДРОСТКА

Subject Terms: periodic disease, clinical case, подросток, семейная средиземноморская лихорадка, генетическое исследование, adolescent, периодическая болезнь, клинический случай, Familial Mediterranean fever, genetic study

Hereditary periodic fever syndromes in adult rheumatology practice ; Наследственные периодические лихорадки в практике взрослого ревматолога

Authors: O. V. Zhelyabina, M. S. Eliseev, M. N. Chikina, О. В. Желябина, М. С. Елисеев, М. Н. Чикина

Source: Modern Rheumatology Journal; Том 12, № 1 (2018); 78-84 ; Современная ревматология; Том 12, № 1 (2018); 78-84 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2018-1

Subject Terms: интерлейкин 1, periodic fever syndromes, familial Mediterranean fever, interleukin-1, периодические лихорадки, семейная средиземноморская лихорадка

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/813/786; Fietta P. Autoinflammatory disease: thehereditary periodic fever syndromes. Acta Biomed. 2004 Aug;75(2):92-9.; Федоров ЕС, Салугина СО, Кузьмина НН. Аутовоспалительные синдромы: что необходимо знать ревматологу. Современная ревматология. 2012;6(2):49-59. [Fedorov ES, Salugina SO, Kuz'mina NN. Autoinflammatory syndromes: What a rheumatologist should know. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012;6(2): 49-59. (In Russ.)]. doi:10.14412/1996-7012-2012-728.; Simon A, van der Meer JW. Patogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan; 292(1):R86-98. Epub 2006 Aug 24.; Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. 2012 Jul;71(7):1177-82. doi:10.1136/annrheumdis-2011-200549. Epub 2012 Feb 29.; Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1b secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007 Sep;56(9):3138-48. doi:10.1002/art.22842; Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77. (In Russ.)]. doi:10.14412/1995-4484-2016-60-77; Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011 May;41(5):1203-17. doi:10.1002/eji.201141550.; Mensa-Vilaro A, Teresa Bosque M, Magri G, et al. Late onset cryopyrin-associated periodic syndrome due to myeloidrestricted somatic NLRP3 mosaicism. Arthritis Rheumatol. 2016 Dec;68(12):3035- 3041. doi:10.1002/art.39770.; Barron K, Athreya B, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Cassidy JT, editor. Textbook of pediatric rheumatology. 6th ed. Elsevier Saunders; 2011. P. 642-60.; Kile RL, Rusk HA. A case of cold urticaria with unusual family history. JAMA. 1940;114:1067-8.; Yamauchi A, Iwata H, Ohnishi H, et al. Interleukin-17 expression in the urticarial rash of familial cold autoinflammatory syndrome: a case report. Br J Dermatol. 2010 Dec;163(6):1351-3. doi:10.1111/j.1365-2133.2010.09978.x. Epub 2010 Nov 4.; Espandar L, Boehlke CS, Kelly MP. First report of keratitis in familial old autoinflammatory syndrome. Can J Ophthalmol. 2014 Jun;49(3):304-6. doi:10.1016/j.jcjo.2014.01.007.; Gerbig AW, Dahinden CA, Mullis P, Hunziker T. Circadian elevation of IL-6 levels in Muckle-Wells syndrome: a disorder of the neuro-immune axis? QJM. 1998 Jul;91(7): 489-92.; Dode C, Le Du N, Cuisset L, et al. New mutations of CIAS that are responsible for Muckle- Wells syndrome and familial cold urticaria: a novel mutation underlies both syndrome. Am J Hum Genet. 2002 Jun;70(6): 1498-506. Epub 2002 Apr 25.; Салугина СО, Федоров ЕС, Кузьмина НН. Современные подходы к диагностике, лечению и мониторингу пациентов с криопирин-ассоциированными периодическими синдромами (CAPS). Современная ревматология. 2016;10(2):4-11. [Salugina SO, Fedorov ES, Kuz'mina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrinassociated periodic syndromes (CAPS). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(2):4-11. (In Russ.)]. DOI:10.14412/1996-7012-2016-2-4-11.; Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, et al. Hearing loss in Muckle- Wells syndrome. Arthritis Rheum. 2013 Mar;65(3):824-31. doi:10.1002/art.37810.; Lieberman A, Grossman ME, Silvers DN. Muckle-Wells syndrome: case report and review of cutaneous pathology. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):290-1.; Goldbach-Mansky R, Daily NJ, Canna SW, et al. Neonatal-Onset Mutisystem Inflammatory Disease Responsive to Interleukine-1 Inhibition. N Engl J Med. 2006 Aug 10;355(6):581-92.; Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008 Aug;58(8): 2432-42. doi:10.1002/art.23620.; Lachmann H, Kone-Paut I, Kuemmerle-Deschner GB, et al. for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416-25. doi:10.1056/NEJMoa0810787.; Simon A, Drewe E, van der Meer JW. Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Clin Pharmacol Ther. 2004 May;75(5):476-83.; Van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinemia D and periodic fever: a new syndrome. Lancet. 1984 May 19; 1(8386):1087-90.; Haas D, Hoffmans GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006 Apr 26;1:13.; Arostegui JI, Anton J, Calvo I, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017 Aug;69(8):1679-1688. doi:10.1002/art.40146. Epub 2017 Jul 5.; Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford). 2004 Apr;43(4):410-5. Epub 2004 Feb 24.; Kuijk LM, Hoffman HL, Neven B, Frenkel J. Episodic autoinflammatory disorders in children. In: Cimas R, Lehman T, editors. Handbook of Systemic Autoimmune Disease. Vol. 6 Pediatrcs in Systemic Autoimmune Disease. Elselvier; 2008. P. 119-35.; Kusuhara K, Nomura A, Nakao F, Hara T. Tumor necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr. 2004 Jan;163(1):30-2. Epub 2003 Nov 11.; Drenth G, van der Meer JW. Hereditary Periodic fever. N Engl J Med. 2001 Dec 13; І345(24):1748-57.; Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptorassociated periodic syndrome (TRAPS an op label, phase II study. Ann Rheum Dis. 2017 Jan; 76(1):173-178. doi:10.1136/annrheumdis-2015-209031. Epub 2016 Jun 7.; La Torre F, Caparello MC, Cimaz R. Canakinumab for the treatment of TNF-receptor associated periodic syndrome. Expert Rev Clin Immunol. 2017 Jun;13(6):513-523. doi:10.1080/1744666X.2017.1324783.; Drenth G, van der Meer JW. Hereditary Periodic fever. N Engl J Med. 2001 Dec 13; 345(24):1748-57.; Федоров ЕС, Салугина СО, Кузьмина НН. Семейная средиземноморская лихорадка (периодическая болезнь): современный взгляд на проблему. Современная ревматология. 2013;7(1):24-30. [Fedorov ES, Salugina SO, Kuz'mina NN. Familial Mediterranean fever (a periodic disease): The present-day view of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(1):24-30. (In Russ.)]. doi:10.14412/1996-7012-2013-2363.; Арутюнян ВМ, Акопян ГС. Периодическая болезнь (этиопатогенетические и клинические аспекты). Москва: МИА; 2000. [Arutyunyan VM, Akopyan GS. Periodicheskaya bolezn' (etiopatogeneticheskie i klinicheskie aspekty) [Periodic disease (etiopathogenetic and clinical aspects)]. Moscow: MIA; 2000.]; Kalinich T, Haffer D, Niehues T, et al. Colchicine Use in Children and Adolescents With Familial Mediterranean Fever. Literature Review and Consensus Statement. Pediatrics. 2007 Feb;119(2):e474-83. Epub 2007 Jan 22.; Алекберова ЗС, Барскова ВГ. Колхицин в ревматологии – вчера и сегодня. Будет ли завтра? Современная ревматология. 2010;4(2):25-9. [Alekberova ZS, Barskova VG. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya revmatologiya = Modern Rheumatology Journal. 2010;4(2):25-9. (In Russ.)]. DOI:10.14412/1996-7012-2010-598.; Ozen S. Familial mediterranean fever: revisiting an ancient disease. Eur J Pediatr. 2002 Aug;161(8):449-54. Epub 2002 Jun 28.; Frenkel J, Kuijk L, Hofhuis W, et al. Anakinra in colchicin resistant Familial Mediterranean Fever in 14th European Paediatric Rheumatology Congress. Sept. 5-9, 2007. Istanbul. Abstr book:252.; Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean Fever and its effect to secondary AA amyloidosis. J Clin Rheumatol. 2004 Jun;10(3):134-7.; Аствацатрян ВА, Торосян ЕХ. Периодическая болезнь у детей. Ереван: Айастан; 1989. [Astvatsatryan VA, Torosyan EKh. Periodicheskaya bolezn' u detei [Periodic disease in children]. Erevan: Aiastan; 1989.]; Akar S, Cetin P, Kalyoncu U. A Nationwide Experience With The Off-label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care Res (Hoboken). 2017 Oct 9. doi:10.1002/acr.23446. [Epub ahead of print].; Ter Haar N, Lachmann H, Еzen S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/ Eurotraps ProjectsTreatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May;72(5):678-85. doi:10.1136/annrheumdis-2011-201268. Epub 2012 Jun 29.; Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9): 1636-44. doi:10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.; De Benedetti F, Anton J, Gattorno M, et al. A Phase III, Pivotal, Umbrella Trial of Canakinumab in Patients With Auto-inflammatory Periodic Fever Syndromes (Colchicine- Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases. 2016;75:615-6.; Lachmann H, Simon A, Anton J, et al. FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes. Annals of the Rheumatic Diseases. 2016;75:616.; Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. J Nephrol. 2018 Feb 14. doi:10.1007/s40620- 018-0475-5. [Epub ahead of print].

Availability: https://mrj.ima-press.net/mrj/article/view/813
https://doi.org/10.14412/1996-7012-2018-1-78-84

Familial mediterranean fever: current view ; Семейная средиземноморская лихорадка: современные представления

Authors: S. A. Atoyan, С. А. Атоян

Source: Medical Genetics; Том 15, № 3 (2016); 3-11 ; Медицинская генетика; Том 15, № 3 (2016); 3-11 ; 2073-7998

Subject Terms: colchicine, Семейная Средиземноморская лихорадка, ген MEFV, колхицин, Hereditary Periodic fevers, Familial Mediterranean fever, MEFV gene

File Description: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/99/87; Sanchez GAM, de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am. 2013;39(4):701-734. doi:10.1016/j.rdc.2013.08.001.; Kastner DL. Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program. 2005;2005(1):74-81. doi:10.1182/asheducation-2005.1.74.; Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140-1146. doi:10.1038/ng.3089.; Shinar Y, Obici L, Aksentijevich I, T.Sarkisian, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599-1605. doi:10.1136/annrheumdis-2011-201271.; Livneh A, Ben-Zvi I. Pearls from the Third Israeli Conference on FMF, other autoinflammatory disorders and AA amyloidosis. Isr Med Assoc J. 2014;16(5):269-270. http://www.ncbi.nlm.nih.gov/pubmed/24979827.; Touitou I, Galeotti C, Rossi-Semerano L, Hentgen V, Piram M, Kone-Paut I. The expanding spectrum of rare monogenic autoinflammatory diseases. Orphanet J Rare Dis. 2013;8:162. doi:10.1186/1750-1172-8-162.; Siegal S. Benign paroxysmal peritonitis. Ann Intern Med. 1945;23(1):1. doi:10.7326/0003-4819-23-1-1.; Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447-1453. doi:10.1002/art.24458.; Sarkisian T, Hayrapetyan H, Beglaryan A, Shahsuvaryan G, Yeghiazaryan A. Molecular diagnosis of familial mediterranean fever in armenians. NEW Armen Med J Vol. 1 (2007), N1, pp33-40. 2007;1:33-40.; ISSAID - The International Society of Systemic Auto-Inflammatory Diseases. http://fmf.igh.cnrs.fr/ISSAID/index.php. Accessed July 22, 2015.; Stoffman N, Magal N, Shohat T, et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 8, 307-310. 2000;(June 1999):307-310.; Mattit H, Joma M, Al-Cheikh S, et al. Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype-genotype correlation. Eur J Med Genet. 49(6):481-486. doi:10.1016/j.ejmg.2006.03.002.; Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum. 2002;31(6):371-376. http://www.ncbi.nlm.nih.gov/pubmed/12077709. Accessed November 24, 2014.; Kishida D, Nakamura A, Yazaki M, Tsuchiya-Suzuki A, Matsuda M, Ikeda S-I. Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations. Arthritis Res Ther. 2014;16(5):439. doi:10.1186/s13075-014-0439-7.; Pagava K, Rauscher B, Korinteli IA, Shonvadze D, Kriegshauser G, Oberkanins C. Familial Mediterranean fever in Georgia. Georgian Med News. 2014;(230):79-82. http://www.ncbi.nlm.nih.gov/pubmed/24940862. Accessed June 14, 2015.; Sarkisian T, Ajrapetian H, Beglarian A, Shahsuvarian G, Egiazarian A. Familial Mediterranean Fever in Armenian population. Georgian Med News. 2008;(156):105-111. http://www.ncbi.nlm.nih.gov/pubmed/18403822. Accessed August 23, 2014.; Jeru I, Duquesnoy P, Fernandes-Alnemri T, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A. 2008;105(5):1614-1619. doi:10.1073/pnas.0708616105.; Jeru I, Hayrapetyan H, Duquesnoy P, Sarkisian T, Amselem S. PYPAF1 nonsense mutation in a patient with an unusual autoinflammatory syndrome: role of PYPAF1 in inflammation. Arthritis Rheum. 2006;54(2):508-514. doi:10.1002/art.21618.; Hentgen V, Grateau G, Stankovic-Stojanovic K, Amselem S, Jeru I. Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? Arthritis Rheum. 2013;65(6):1654-1662. doi:10.1002/art.37935.; Ben-Zvi I, Herskovizh C, Kukuy O, Kassel Y, Grossman C, Livneh A. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis. 2015;10(1):34. doi:10.1186/s13023-015-0252-7.; Ben-Chetrit E, Peleg H, Aamar S, Heyman SN. The spectrum of MEFV clinical presentations-is it familial Mediterranean fever only? Rheumatology (Oxford). 2009;48(11):1455-1459. doi:10.1093/rheumatology/kep296.; Rubartelli A. Autoinflammatory diseases. Immunol Lett. 2014;161(2):226-230. doi:10.1016/j.imlet.2013.12.013.; Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol. 2013;147(3):242-275. doi:10.1016/j.clim.2013.04.008.; Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-325. http://www.ncbi.nlm.nih.gov/pubmed/15030775. Accessed January 5, 2016.; Mansfield E, Chae JJ, Komarow HD, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood. 2001;98(3):851-859. http://www.ncbi.nlm.nih.gov/pubmed/11468188. Accessed December 30, 2015.; The International FMF Consortium. Ancient Missense Mutations in a New Member of the RoRet Gene Family Are Likely to Cause Familial Mediterranean Fever. Cell. 1997;90(4):797-807. doi:10.1016/S0092-8674(00)80539-5.; A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25-31. doi:10.1038/ng0997-25.; Grandemange S, Aksentijevich I, Jeru I, Gul A, Touitou I. The regulation of MEFV expression and its role in health and familial Mediterranean fever. Genes Immun. 2011;12(7):497-503. doi:10.1038/gene.2011.53.; Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol. 2011;7(2):105-112. doi:10.1038/nrrheum.2010.181.; Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45(6):746-750. doi:10.1093/rheumatology/kei279.; Yang R-Z, Lee M-J, Hu H, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006;3(6):e287. doi:10.1371/journal.pmed.0030287.; Yamada T, Okuda Y, Takasugi K, et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid. 2003;10(1):7-11. http://www.ncbi.nlm.nih.gov/pubmed/12762135. Accessed April 11, 2016.; Jeru I, Sarkisian T, Hayrapetyan H, Duquesnoy P, et al. Involvement of the modifier gene of a human Mendelian disorder in a negative selection process. PLoS One. 2009;4(10):e7676. doi:10.1371/journal.pone.0007676.; Cazeneuve C, Sarkisian T, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67(5):1136-1143. doi:10.1016/S0002-9297(07)62944-9.; Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5(1):1. doi:10.1186/1471-2350-5-4.; Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1b biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol. 2013;45(1):117-130. doi:10.1007/s12016-013-8358-y.; Caso F, Cantarini L, Lucherini OM, et al. Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol. 2014;24(3):381-389. doi:10.3109/14397595.2013.843755.; Tamir N, Langevitz P, Zemer D, et al. Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. Am J Med Genet. 1999;87(1):30-35. http://www.ncbi.nlm.nih.gov/pubmed/10528243. Accessed December 13, 2014.; Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 1998;77(4):268-297. http://www.ncbi.nlm.nih.gov/pubmed/9715731. Accessed September 20, 2014.; Ben-Zvi I, Brandt B, Berkun Y, Lidar M, Livneh A. The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). Gene. 2012;491(2):260-263. doi:10.1016/j.gene.2011.10.005.; Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever - are they more frequent? Semin Arthritis Rheum. 2007;36(5):316-321. doi:10.1016/j.semarthrit.2006.11.002.; Г.Г. Амарян, К.Г. Мирзабекян, С.Г. Казарян, А.С. Баблоян. Клинико-генетическая характеристика спаечной кишечной непроходимости при периодической болезни у детей. http://www.medlib.am/articles/Amaryan(HB-09-4).pdf. Accessed March 12, 2014.; Karban A, Dagan E, Eliakim R, et al. Prevalence and significance of mutations in the familial Mediterranean fever gene in patients with Crohn’s disease. Genes Immun. 2005;6(2):134-139. doi:10.1038/sj.gene.6364156.; Sever F, Sever M, Sanal S, Yalсэn M, Berdeli A. [Familial Mediterranean fever with pulmonary manifestations alone; early diagnosis with genetic analysis]. Tuberk Toraks. 2012;60(4):380-384. http://www.ncbi.nlm.nih.gov/pubmed/23289470. Accessed September 20, 2014.; Salah S, Hegazy R, Ammar R, Sheba H, Abdelrahman L. MEFV gene mutations and cardiac phenotype in children with familial Mediterranean fever: a cohort study. Pediatr Rheumatol Online J. 2014;12:5. doi:10.1186/1546-0096-12-5.; Altug U, Ensari C, Sayin DB, Ensari A. MEFV gene mutations in Henoch-Schоnlein purpura. Int J Rheum Dis. 2013;16(3):347-351. doi:10.1111/1756-185X.12072.; Barzilai A, Langevitz P, Goldberg I, et al. Erysipelas-like erythema of familial Mediterranean fever: Clinicopathologic correlation. J Am Acad Dermatol. 2000;42(5):791-795. doi:10.1067/mjd.2000.103048.; Peleg H, Ben-Chetrit E. The kidney in familial Mediterranean fever. J Rheumatol. 2013;40(12):1948-1950. doi:10.3899/jrheum.131135.; Gharabaghi MA, Behdadnia A, Gharabaghi MA, Abtahi H. Hypoadrenal syndrome in a patient with amyloidosis secondary to familial Mediterranean fever. BMJ Case Rep. 2013;2013. doi:10.1136/bcr-2012-007991.; Jarjour RA, Dodaki R. Arthritis patterns in familial Mediterranean fever patients and association with M694V mutation. Mol Biol Rep. 2011;38(3):2033-2036. doi:10.1007/s11033-010-0326-5.; Alayli G, Durmus D, Ozkaya O, Sen HE, Genc G, Kuru O. Frequency of juvenile fibromyalgia syndrome in children with familial Mediterranean fever: effects on depression and quality of life. Clin Exp Rheumatol. 29(6 Suppl 69):S127-S132. http://www.ncbi.nlm.nih.gov/pubmed/22243560. Accessed September 21, 2014.; Mattiassich G, Semlitsch G, Nadler K, Rainer F. Familial Mediterranean fever without fever as a cause of monoarthritis. BMJ Case Rep. 2013;2013. doi:10.1136/bcr-2012-008395.; Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial mediterranean fever. Arthritis Rheum. 1997;40(10):1879-1885. doi:10.1002/art.1780401023.; Demirkaya E, Acikel C, Gul A, et al. Developing a new severity score for FMF. Pediatr Rheumatol. 2013;11(Suppl 1):A81. doi:10.1186/1546-0096-11-S1-A81.; Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35(1):57-64. doi:10.1016/j.semarthrit.2005.02.002.; Саркисян ТФ, Айрапетян АС, Шахсуварян ГР Молекулярная диагностика семейной средиземноморской лихорадки ( периодической болезни ) среди армян. Новый армянский медицинский журнал. 2007;1. http://www.ysmu.am/images/stories/downloads/NAMJ/Int%20v1n1/Rus/4.pdf; Cazeneuve C, Sarkisian T, Pкcheux C, et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet. 1999;65(1):88-97. doi:10.1086/302459.; Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28(1):48-59. doi:10.1016/S0049-0172(98)80028-0.; Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72-76. doi:10.1016/j.autrev.2012.07.025.; La Regina M, Ben-Chetrit E, Gasparyan AY, Livneh A, Ozdogan H, Manna R. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol. 31(3 Suppl 77): 41-46. http://www.ncbi.nlm.nih.gov/pubmed/24064013. Accessed January 19, 2015.; Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail. 2013;35(8):1071-1074. doi:10.3109/0886022X.2013.811345.; Estublier C, Stankovic Stojanovic K, Bergerot J-F, Broussolle C, Sиve P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. 2013;80(6):645-649. doi:10.1016/j.jbspin.2013.03.004.; Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol. 2012;167(3):382-390. doi:10.1111/j.1365-2249.2011.04535.x.; Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65:223-244. doi:10.1146/annurev-med-061512-150641.; Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol. 21(4):509-514.; Ter Haar NM, Frenkel J. Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol. 2014;26(3):252-258. doi:10.1097/BOR.0000000000000059.

Availability: https://www.medgen-journal.ru/jour/article/view/99
https://doi.org/10.1234/XXXX-XXXX-2016-3-3-11

Антибиотикорезистентность Escherichia coli кишечной микробиоты у больных семейной средиземноморской лихорадкой

Authors: ПЕПОЯН А.З., БАЛАЯН М.А., АРУТЮНЯН Н.А., ГРИГОРЯН АШХЕН ГРИГОРЬЕВНА, ТЦАТУРЯН В.В., МАНВЕЛЯН А.М., ДИЛАНЯН Е., ПИЦЕНО И., ТОРОК Т.

Subject Terms: СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА,КЛИНИЧЕСКИЙ БАКТЕРИОЛОГИЧЕСКИЙ АНАЛИЗ,ДНК-МИКРОЧИПЫ ВЫСОКОЙ ПЛОТНОСТИ,PHYLOCHIPTM,ESCHERICHIA,АНТИБИОТИКОРЕЗИСТЕНТНОСТЬ,ПРОБИОТИК,FAMILIAL MEDITERRANEAN FEVER,CLINICAL BACTERIOLOGICAL ANALYSIS,HIGH-DENSITY DNA-MICROCHIPS,PHYLOCHIP,ANTIBIOTIC RESISTANCE,PROBIOTIC

File Description: text/html

Availability: http://cyberleninka.ru/article/n/antibiotikorezistentnost-escherichia-coli-kishechnoy-mikrobioty-u-bolnyh-semeynoy-sredizemnomorskoy-lihoradkoy
http://cyberleninka.ru/article_covers/16084106.png

Некоторые клинические характеристики крови у больных семейной средиземноморской лихорадкой армянской популяции

Authors: ПЕПОЯН АСТГИК ЗАВЕНОВНА, АРУТЮНЯН Н., ГРИГОРЯН А., ЦАТУРЯН В.В., МАНВЕЛЯН А.М., ДИЛАНЯН Е., БАЛАЯН М.А., ТОРОК Т.

Subject Terms: СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА, С-РЕАКТИВНЫЙ БЕЛОК, ЛАКТАЗНАЯ АКТИВНОСТЬ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/nekotorye-klinicheskie-harakteristiki-krovi-u-bolnyh-semeynoy-sredizemnomorskoy-lihoradkoy-armyanskoy-populyatsii
http://cyberleninka.ru/article_covers/15840399.png

DYSFUNCTION OF COMPLEMENT SYSTEM IN FAMILIAL MEDITERRANEAN FEVER ; ДИСФУНКЦИЯ СИСТЕМЫ КОМПЛЕМЕНТА ПРИ СЕМЕЙНОЙ СРЕДИЗЕМНОМОРСКОЙ ЛИХОРАДКЕ

Authors: G. M. Mkrtchyan, L. P. Hovhannisyan, A. A. Ayvazyan, E. Y. Nazaretyan, A. S. Boyajyan, Г. М. Мкртчян, Л. П. Оганесян, А. А. Айвазян, Э. Е. Назаретян, А. С. Бояджян

Source: Medical Immunology (Russia); Том 11, № 1 (2009); 85-90 ; Медицинская иммунология; Том 11, № 1 (2009); 85-90 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2009-1

Subject Terms: семейная средиземноморская лихорадка, classic complement pathway, familial mediterranean fever, классический путь комплемента

File Description: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/221/223; Akcan Y., Bayraktar Y., Arslan S., VanThiel D.H., Zerrin B.C., Yildiz O. The importance of serial measurements of cytokine levels for the evaluation of their role in pathogenesis in familial Mediterraean fever//Eur J Med Res. -2003. -Vol. 8. -P. 304-306.; Ayesh S.K., Azar Y., Babior B.M., Matzner Y. Inactivation of Interleukin-8 by the CSa-Inactivating Protease From Serosal Fluid//Blood. -1993. -Vol. 81, N 6. -P. 1424-1427.; Ben-Chetrit E., Backenroth R., Haimov-Kochman R., Pizov G. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis//Ann Rheum Dis. -1998. -Vol. 57, N 4. -P. 259-260.; Ben-Chetrit E., Familial Mediterranean fever (FMF) and renal AA amyloidosis. Phenotype-genotype correlation, treatment and prognosis//J. Nefrol. -2003. -Vol. 16. -P. 431-434.; Ben-Chetrit E., Levy M. Colchicine update -1998//Semin Arthritis Rheum. -1998. -Vol. 28. -P. 48-59.; Ben-Chetrit E., Levy M. Familial Mediterranean fever//Lancet. -1998. -Vol. 351. -P. 659-664.; Bíró A., Rovó Z., Papp D., Cervenak L., Varga L., F st G., Thielens N.M., Arlaud G.J., Prohászka Z. Studies on the interactions between C-reactive protein and complement proteins//Immunology. -2007. -Vol. 121, N 1. -P. 40-50.; Cerquaglia C., Diaco M., Nucera G., La Regina M., Montalto M., Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean fever (FMF) with colchicine or analogues: an update//Curr. Drug. Targets Inflamm. Allergy. -2005. -Vol. 4, N 1. -P. 117-124.; French FMF Consortium. A candidate gene for familial Mediterranean fever//Nat. Genet. -1997. -Vol. 17. -P. 25-31.; Gang N., Drenth J.P., Langevitz P. Activation of the cytokine network in familial Mediterranean fever//J. Rheumatol. -1999. -Vol. 26. -P. 890-897.; Goldfinger S.E. Colchicine for familial Mediterranean fever//N. Engl. J. Med. -1972. -Vol. 287. -P. 1302.; Holers V.M. The complement system as a therapeutic target in autoimmunity//Clin. Immunol. -2003. -Vol. 107, N 3. -P. 140-151.; International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever//Cell. -1997. -Vol. 90. -P. 797-807.; Korkmaz C., Ozdogan H., Kasapcopur O.,Yazici H. Acute phase response in familial Mediterranean fever//Ann. Rheum. Dis. -2002. -Vol. 61, N 1. -P. 79-81.; Le G.T., Abbenante G., Fairlie D.P. Profiling the enzymatic properties and inhibition of human complement factor B//J. Biol. Chem. 2007. -Vol. 282, N 48. -P. 34809-34816.; Lidar M., Scherrman J.M., Shinar Y., Chetrit A., Niel E., Gershoni-Baruch R., Langevitz P., Livneh A. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization//Semin. Arthritis Rheum. -2004. -Vol. 33, N 4. -P. 273-282.; Linneh A., Langevitz P., Zemer D., Zaks N., Kees S., Lidar T. Criteria for the diagnosis of familial Mediterranean fever//Arthritis Rheum. -1997. -Vol. 40. -P. 1879-1885.; Matzner Y., Abedat S., Shapiro E., Eisenberg S., Bar-Gil-Shitrit A., Stepensky P., Calco S., Azar Y.,Urieli-Shoval S. Expression of the familial Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures//Blood. -2000. -Vol. 96, N 2. -P. 727-731.; Medlej-Hashim M., Loiselet J., Lefranc G.,Megarbane A. Familial Mediterranean fever (FMF): from diagnosis to treatment//Sante. -2004. -Vol. 14, N 4. -P. 261-266.; Melamed A., Cabili S., Zakuth V., Spirer Z. The immune regulation in familial Mediterranean fever//J. Clin. Lab. Immunol. -1988. -Vol. 26. -P. 125-128.; Mйry J.P., Kenouch S. Familial Mediterranean fever associated amyloidosis//Renal Failure. -1993. -Vol. 15. -P. 379-384.; Mkrtchyan G.M., Boyajyan A.S.,Ayvazyan A.A., Beglaryan A.A. Classical pathway complement activity in Familial Mediterranean fever//Clin. Biochem. -2006. -Vol. 39, N 7. -P. 688-691.; Mkrtchyan G.M., Boyajyan A.S.,Karageuzyan K.G., Ayvazyan A.A., Pashinyan S.H., Nazaretyan E.Ye. Protein composition of circulating immune complexes in patients with Periodic disease complicated or not complicated by renal amyloidosis//Dokl. Biol. Sci. -2002. -Vol. 385. -P. 329-330.; Mollnes T.E., Song W.-C., Lambris J.D. Complement in inflammatory tissue damage and disease//Trends Immunol. Today. -2002. -Vol. 23, N2. -P. 61-66.; Morgan B.P. Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates//Methods in Molecular Biology. Complement Methods and Protocols/Ed. Morgan B.P. -Humana Press, 2000. -P. 61-71.; Odabas A.R., Cetinkaya R., Selcuk Y., Keles S., Bilen H. Serum C-reactive protein levels during attack-free periods of familial Mediterranean fever//The Pain Clinic -2002. -Vol. 13, N 4. -P. 319-321.; Schattner A., Lachmi M., Livneh A., Pras M., Hahn T. Tumor necrosis factor in familial Mediterranean fever//Am. J. Med. -1991. -Vol. 90. -P. 434-438.; Sj berg A.P., Trouw L.A., McGrath F.D.,Hack C.E., Blom A.M. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein//J. Immunol. -2006. -Vol. 176, N 12. -P. 7612-7620.; Szalai A.J., van Ginkel F.W., Wang Y., McGhee J.R., Volanakis J.E. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component//J. Immunol. -2000. -Vol. 165, N 2. -P. 1030-1035.; Van Oss C.J. The human complement system in health and disease//Marcel Decker. Inc., 1998.; Vinceneux P., Pouchot J. Maladie pйriodique, symptomatologie clinique et biologique//Presse Med.-2005. -Vol. 34, N 13. -P. 938-946.; Whaley K., North J. Haemolytic assays for whole complement activity and individual components//Complement. A Practical Approach/Ed. Doods A.W., Sim R.B. -Oxford University Press, 1997. -P. 9-47.; Yalinkaya F., Cakar N., Acar B., Tutar E., Guriz H., Elhan A.N., Ozturk S., Kansu A.; Ince E., Atalay S., Girgin N., Dogru U., Aysev D., Ekim M. The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study//Rheumatol. Int.-2007. -Vol. 27, N 6. -P. 517 -522.; https://www.mimmun.ru/mimmun/article/view/221

Availability: https://www.mimmun.ru/mimmun/article/view/221
https://doi.org/10.15789/1563-0625-2009-1-85-90

АУТОВОСПАЛИТЕЛЬНЫЕ СИНДРОМЫ В ПРАКТИКЕ ВРАЧА-ПЕДИАТРА

Authors: НЕДЕЛЬСКАЯ С.Н., ЖИЛЕНКО И.А., МЕРЕЖКО А.С., ШАПРАН А.В.

Subject Terms: АУТОВОСПАЛИТЕЛЬНЫЕ СИНДРОМЫ,AUTOINFLAMMATORY SYNDROMES,СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА,FAMILIAL MEDITERRANEAN FEVER,КРИОПИРИН-АССОЦИИРОВАННЫЕ СИНДРОМЫ,CRYOPYRIN-ASSOCIATED SYNDROMES,ГИПЕР-IGD-СИНДРОМ,АВТОЗАПАЛЬНі СИНДРОМИ,СіМЕЙНА СЕРЕДЗЕМНОМОРСЬКА ЛИХОМАНКА,КРіОПіРИН-АСОЦіЙОВАНі СИНДРОМИ,ГіПЕР-IGD-СИНДРОМ,HYPER-IGD-SYNDROME

File Description: text/html

Availability: http://cyberleninka.ru/article/n/autovospalitelnye-sindromy-v-praktike-vracha-pediatra
http://cyberleninka.ru/article_covers/16489644.png

СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА (ПАРОКСИЗМАЛЬНЫЙ ПОЛИСЕРОЗИТ, СЕМЕЙНЫЙ РЕЦИДИВИРУЮЩИЙ ПОЛИСЕРОЗИТ, ПЕРИОДИЧЕСКАЯ БОЛЕЗНЬ). 31

Authors: Шамов, Ибрагим

Subject Terms: СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА, КЛИНИКА, ДИАГНОСТИКА, ЛЕЧЕНИЕ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/semeynaya-sredizemnomorskaya-lihoradka-paroksizmalnyy-poliserozit-semeynyy-retsidiviruyuschiy-poliserozit-periodicheskaya-bolezn
http://cyberleninka.ru/article_covers/15804285.png

ПЕРИОДИЧЕСКИЕ ЛИХОРАДКИ В ПРАКТИКЕ ДЕТСКОГО ВРАЧА

Authors: Шиляев, Р., Копилова, Е., Харитонова, Е., Менагаришвили, И.

Subject Terms: ДЕТИ, АУТОВОСПАЛИТЕЛЬНЫЕ СИНДРОМЫ, РЕЦИДИВИРУЮЩАЯ ЛИХОРАДКА, СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА

File Description: text/html

Availability: http://cyberleninka.ru/article/n/periodicheskie-lihoradki-v-praktike-detskogo-vracha
http://cyberleninka.ru/article_covers/15565179.png

СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА (ПЕРИОДИЧЕСКАЯ БОЛЕЗНЬ): СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУ

Authors: Федоров, Евгений, Салугина, С., Кузьмина, Н.

Subject Terms: СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА, АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ, МОНОГЕННЫЕ НАСЛЕДСТВЕННЫЕ ЗАБОЛЕВАНИЯ, КОЛХИЦИН

File Description: text/html

Availability: http://cyberleninka.ru/article/n/semeynaya-sredizemnomorskaya-lihoradka-periodicheskaya-bolezn-sovremennyy-vzglyad-na-problemu
http://cyberleninka.ru/article_covers/14421458.png

CARDIOPATHIC AMYLOIDOSIS AS A PATHOGENETICAL FACTOR FOR DEVELOPMENT OF MYOCARDIAL INFARCTION AT FAMILIAL MEDITERRANEAN FEVER

Authors: Hambardzumyan, S.

Subject Terms: СЕМЕЙНАЯ СРЕДИЗЕМНОМОРСКАЯ ЛИХОРАДКА, КАРДИОПАТИЧЕСКИЙ АМИЛОИДОЗ, МОРФОЛОГИЯ, ИНФАРКТ МИОКАРДА

File Description: text/html

Availability: http://cyberleninka.ru/article/n/cardiopathic-amyloidosis-as-a-pathogenetical-factor-for-development-of-myocardial-infarction-at-familial-mediterranean-fever
http://cyberleninka.ru/article_covers/15154377.png